Leiomyosarcoma: Epidemiology and treatment approaches

Abstract

Author(s): Dhwani Bartwal, Shikhar Gupta, Rashmi Mishra, Prabhat Sharma, Shriniwas, Nikhil Chandra Mahajan

Background: Leiomyosarcoma (LMS) is an uncommon type of tumour found in the uterus, comprising about one percent of cancers in women and playing a substantial role in uterine cancer fatalities. The resemblance to benign leiomyomas complicates pre-surgery detection, possibly leading to improper use of myomectomy and morcellation, causing concerns. Managing Uterine Leiomyosarcoma (ULMS) is particularly challenging due to its aggressive nature and resistance to standard therapies. Predictive algorithms provide accurate forecasts, although the time of diagnosis is critical for survival.

Aim of the study: This study evaluates the effectiveness of existing surgical and medicinal treatments for ULMS, concentrating on targeted therapy and examining the influence of uterine morcellation on gynaecologic surgical practices. The main goal is to improve knowledge of ULMS, investigate early detection techniques, and assess new treatments.

Materials and Methods: Study employs a comprehensive analysis of existing literature, emphasizing surgical techniques, medicinal approaches, and the effects of certain medicines including olaratumab, trabectedin, and pazopanib. The current examination focuses on aromatase inhibitors and immunotherapies.

Results: However, treating ULMS is challenging, Food and Drug Administration (FDA)-approved targeted therapies have shown efficacy against uterine and other LMSs. The present research concentrates on creating methods for detecting diseases at an early stage and exploring new treatments, such as aromatase inhibitors and immunotherapies.

Conclusion: Study emphasizes the necessity for enhanced detection methods for ULMS due to its deceptive resemblance to benign tumours. Investigation of new treatments and the effects of uterine morcellation on surgical techniques is crucial for improving the management of ULMS, even with the effectiveness of FDA-approved therapies.

Share this article